arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Passage BIO, Inc.

PASG
$4.89 ▲ +0.08 (+1.66%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
31 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Passage BIO, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $15.7M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -146.7%
FCF / Share $-2.86
Trailing P/E
Price / Book 3.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-7.82M
↑ +16.7%
FCF / Share Free cash flow per share
$-2.86
↑ +29.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters